A personalized mRNA vaccine combined with pembrolizumab reduced the risk of melanoma returning or death by 42% in a phase III trial.
A personalized mRNA vaccine combined with pembrolizumab reduced the risk of melanoma returning or death by 42% in a phase III trial.